NCT07009262View on ClinicalTrials.gov

A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks

RecruitingOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

April 21, 2025

Primary Completion Date

April 7, 2026

Study Completion Date

April 7, 2026

Conditions
Hereditary Angioedema
Interventions
OTHER

Inapplicable

Inapplicable

Trial Locations (1)

22030

RECRUITING

KalVista Investigative Site, Fairfax

Sponsors
All Listed Sponsors
collaborator

US Hereditary Angioedema Association

UNKNOWN

lead

KalVista Pharmaceuticals, Ltd.

INDUSTRY

NCT07009262 - A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks | Biotech Hunter | Biotech Hunter